CA77.1

CA77.1 (CA) is a synthetic compound that activates chaperone-mediated autophagy (CMA) by increasing the expression of the lysosomal receptor for this pathway, LAMP2A, in lysosomes. CA77.1 is a derivative of earlier compound AR7(HY-101106), which shows potent CMA activation in vitro but is not suitable for in vivo use.^[1][2][3] CA77.1 is able to activate CMA in vivo, and demonstrates brain penetrance and favorable pharmacokinetics. It has been shown in animal studies that in vivo administration of CA77.1 to enhance chaperone-mediated autophagy, may help to degrade toxic pathogenic protein products such as tau proteins and has potential applications in the treatment of Alzheimer's disease^[4][5] particularly in improving both behavior and neuropathology in PS19 mice models.

CA77.1

Identifiers
IUPAC name N-[4-(6-chloroquinoxalin-2-yl)phenyl]acetamide
CAS Number	2412270-22-3 N[ChemSpider]
PubChem CID	146439211
ChemSpider	114641988
CompTox Dashboard (EPA)	DTXSID701336851
Chemical and physical data
Formula	C16H12ClN3O
Molar mass	297.74 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(=O)NC1=CC=C(C=C1)C2=CN=C3C=C(C=CC3=N2)Cl
InChI InChI=1S/C16H12ClN3O/c1-10(21)19-13-5-2-11(3-6-13)16-9-18-15-8-12(17)4-7-14(15)20-16/h2-9H,1H3,(H,19,21) Key:ZQXMPDVGBWOTBY-UHFFFAOYSA-N